Dr Jones wrote to Armour to say that, in particular, their product should not be given to "previously untreated seronegative patients" and that he was "particularly averse to its prescription for children."
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation
Key Person(s)
Dr Peter M Jones